FRM
SYRS

Fox Run Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Fox Run Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,283
Closed -$70K – 654
2021
Q2 		$70K Buy
+1,283
New +$75.9K 0.06% 326

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fox Run Management's SYRS Position: Q3 2021 in Review

Fox Run Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2021, closing a stake of 1,283 shares — an estimated $70K sold.

Fox Run Management first reported a position in SYRS in Q2 2021 and held it in 1 quarter. The position peaked at $70K in Q2 2021. 100 funds tracked by Wall St. Rank hold SYRS as of Q3 2021.

  • Fox Run Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Fox Run Management sold 1,283 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $70K.
  • Fox Run Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Fox Run Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $70K in Q2 2021.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Fox Run Management's 13F filing for Q3 2021, filed 15 Nov 2021.